Bristol-Myers Squibb (BMS) is reported to have reached a deal to license its AIDS drug Reyataz to two generic drug manufacturers in the developing world free of charge, one of the first such agreements involving a second-line AIDS treatment.
Under the deal to be announced today, BMS will grant a royalty-free license to South Africa’s Aspen PharmaCare Holdings and India’s Emcure Pharmaceuticals to make and sell atazanavir, the molecule Reyataz is based on, in sub-Saharan Africa, The Wall Street Journal reported.
Reyataz is a relatively new AIDS drug considered especially effective when used in a “cocktail” combination with Abbott Laboratories’ Norvir.
BMS received US marketing approval for Reyataz in 2003. The drug’s patent runs out in 2017.